NCT03495323 2021-04-15
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
4 trialsNCT02124148 2020-04-01
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02555644 2019-02-15
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02514603 2017-05-22
A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
Eli Lilly and Company
Phase 1 Completed